Among adults with cancer receiving their first TKI, rosuvastatin use was associated with a lower rate of major adverse cardiovascular events than atorvastatin use; this observational finding is compatible with, but does not establish, a CYP3A4-mediated interaction.
Rosuvastatin was associated with a lower rate of major adverse cardiovascular events (MACE) than atorvastatin in TKI-treated patients with cancer in the primary analysis.
A pooled comparison of non-CYP3A4-metabolized statins versus atorvastatin gave a concordant result.
The proportional-hazards assumption was violated in the primary comparison, so the hazard ratio was interpreted as a time-averaged association.
The early-persistence Day-180 estimate was imprecise and its confidence interval included no difference.
The study was designed as an active-comparator, new-user target trial emulation using the TriNetX database.
The authors state the findings are compatible with, but do not establish, a CYP3A4-mediated drug interaction, and list important limitations.
This study looked at adults with cancer who were starting their first tyrosine kinase inhibitor (TKI), a type of targeted cancer drug, and who also began taking a statin. Many TKIs and atorvastatin are processed by the same liver enzyme (CYP3A4), which raises the possibility of drug interactions. Rosuvastatin and pitavastatin largely avoid this enzyme. Using a large electronic health records database, the researchers compared patients on different statins after matching them on many characteristics, mimicking a clinical trial. Patients taking rosuvastatin had about 16% fewer major cardiovascular events (such as heart attack or stroke) over up to 3 years than those taking atorvastatin. A pooled comparison of statins that avoid this enzyme versus atorvastatin gave a similar result. However, the difference was not constant over time, and an early six-month estimate was imprecise and did not show a clear difference. This research suggests that statin choice might matter for heart health in people on TKIs, possibly because of drug interactions, but it cannot prove this. Because the study was observational, unmeasured differences between patients could explain some of the results, and the timing of TKI and statin use was not perfectly aligned in some patients. The authors call for prospective studies to confirm the findings.
Liao J, Chang W, Jhou H, Chen H, Chen P, Lee C. (2026). Association of Non-Cytochrome P450 3A4-Metabolized Statins Versus Atorvastatin With Major Adverse Cardiovascular Events in Patients With Cancer Receiving Tyrosine Kinase Inhibitors: A Propensity Score-Matched Target Trial Emulation.. Journal of the American Heart Association. https://doi.org/10.1161/JAHA.126.053141